Drug Trial Radar · NCT04804605
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,220
Actual
Start
Feb 25, 2021
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Arcutis Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a Phase 3, multicenter, open-label extension study of the long-term safety of roflumilast cream 0.15% (completers of studies ARQ-151-311 or ARQ-151-312 aged ≥6 years and ARQ-151-315 rollovers who turned 6 years of age on study) or roflumilast cream 0.05% (ARQ-151-315 rollovers aged 2 to 5 years). Participants with mild to moderate atopic dermatitis (AD) applied roflumilast cream once daily (qd) for up to 52 weeks.
Conditions
- Atopic Dermatitis Eczema
Interventions
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Drug
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE)Time frame: Up to 52 weeks
Locations
92 sites in 2 countries. Site status is shown where the registry gives one.
Arcutis Clinical Site 112
Birmingham, Alabama
Arcutis Clinical Site 73
Birmingham, Alabama
Arcutis Clinical Site 63
Scottsdale, Arizona
Arcutis Clinical Site 106
Bryant, Arkansas
Arcutis Clinical Site 116
Fort Smith, Arkansas
Arcutis Clinical Site 69
Beverly Hills, California
Arcutis Clinical Site 81
Inglewood, California
Clinical Site 08
San Francisco, California
Arcutis Clinical Site 31
Santa Monica, California
Arcutis Clinical Site 130
Thousand Oaks, California
Arcutis Clinical Site 123
Centennial, Colorado
Arcutis Clinical Site 59
Coral Gables, Florida
Arcutis Clinical Site 72
Coral Gables, Florida
Arcutis Clinical Site 79
Delray Beach, Florida
Arcutis Clinical Site 103
Hollywood, Florida
Clinical Site 04
Jacksonville, Florida
Arcutis Clinical Site 15
Largo, Florida
Arcutis Clinical Site 67
Miami, Florida
Arcutis Clinical Site 95
Miami, Florida
Arcutis Clinical Site 68
Miami, Florida
Arcutis Clinical Site 29
Sanford, Florida
Clinical Site 01
Tampa, Florida
Arcutis Clinical Site 138
Wellington, Florida
Arcutis Clinical Site 47
Sandy Springs, Georgia
Arcutis Clinical Site 145
Boise, Idaho
Arcutis Clinical Site 13
Rolling Meadows, Illinois
Arcutis Clinical Site 93
Clarksville, Indiana
Clinical Site 22
Plainfield, Indiana
Arcutis Clinical Site 114
West Lafayette, Indiana
Clinical Site 03
Louisville, Kentucky
Arcutis Clinical Site 80
Covington, Louisiana
Arcutis Clinical Site 85
Lake Charles, Louisiana
Arcutis Clinical Site 24
Metairie, Louisiana
Arcutis Clinical Site 76
Rockville, Maryland
Arcutis Clinical Site 94
Bay City, Michigan
Arcutis Clinical Site 88
Clarkston, Michigan
Arcutis Clinical Site 58
Clinton Township, Michigan
Arcutis Clinical Site 66
Detroit, Michigan
Arcutis Clinical Site 132
Troy, Michigan
Clinical Site 10
New Brighton, Minnesota
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.